Phase 4
Completed N=28
Treatment of Upper Extremity Deep-Vein Thrombosis
Source: ClinicalTrials.gov NCT00245856 ↗Enrolled (actual)
28
Serious AEs
3.0%
Results posted
Feb 2013
Primary outcomePrimary: Percentage of Participants That Died at 3 Months — 8; 0 percentage of participants
Summary
The purpose of this study is to document the long-term outcome or prognosis of patients diagnosed with upper extremity deep-vein thrombosis who are treated with Fragmin (dalteparin sodium injection) for three months.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percentage of Participants That Died at 3 Months |
8; 0 | — |
| PRIMARY New Venous Thromboembolism at 3 Months |
— | — |
| SECONDARY Bleeding Events |
1 | — |
Eligibility Criteria
Inclusion Criteria
- Patients with confirmed upper extremity DVT diagnosed by ultrasound imaging or venogram
Exclusion Criteria
- Active, clinically significant bleeding
- Known hypersensitivity to heparin or low-molecular weight heparin
- Currently pregnant or less than 1 week post-partum
- Acquired bleeding diathesis
- Known inherited bleeding disorder
- Renal failure
- Extremes of weight
- Poor performance status
- Unable to return for repeat diagnostic testing or follow-up visits
Data sourced from ClinicalTrials.gov (NCT00245856). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.